These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
181 related articles for article (PubMed ID: 26298530)
1. Efficacy and safety of nab-paclitaxel combined with carboplatin in Chinese patients with melanoma. Guo YQ; Ding Y; Li DD; Li JJ; Peng RQ; Wen XZ; Zhang X; Zhang XS Med Oncol; 2015 Sep; 32(9):234. PubMed ID: 26298530 [TBL] [Abstract][Full Text] [Related]
2. A phase 2 clinical trial of nab-paclitaxel in previously treated and chemotherapy-naive patients with metastatic melanoma. Hersh EM; O'Day SJ; Ribas A; Samlowski WE; Gordon MS; Shechter DE; Clawson AA; Gonzalez R Cancer; 2010 Jan; 116(1):155-63. PubMed ID: 19877111 [TBL] [Abstract][Full Text] [Related]
3. A randomized phase 2 study of temozolomide and bevacizumab or nab-paclitaxel, carboplatin, and bevacizumab in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group study, N0775. Kottschade LA; Suman VJ; Perez DG; McWilliams RR; Kaur JS; Amatruda TT; Geoffroy FJ; Gross HM; Cohen PA; Jaslowski AJ; Kosel ML; Markovic SN Cancer; 2013 Feb; 119(3):586-92. PubMed ID: 22915053 [TBL] [Abstract][Full Text] [Related]
4. A phase II study of nab-paclitaxel plus carboplatin in combination with thoracic radiation in patients with locally advanced non-small-cell lung cancer. Hasegawa T; Futamura Y; Horiba A; Yoshida T; Suzuki T; Kato T; Kaito D; Ohno Y; Iida T; Hayashi S; Sawa T J Radiat Res; 2016 Jan; 57(1):50-4. PubMed ID: 26442970 [TBL] [Abstract][Full Text] [Related]
5. A phase II trial of nab-paclitaxel (ABI-007) and carboplatin in patients with unresectable stage IV melanoma : a North Central Cancer Treatment Group Study, N057E(1). Kottschade LA; Suman VJ; Amatruda T; McWilliams RR; Mattar BI; Nikcevich DA; Behrens R; Fitch TR; Jaslowski AJ; Markovic SN Cancer; 2011 Apr; 117(8):1704-10. PubMed ID: 21472717 [TBL] [Abstract][Full Text] [Related]
6. Effect of paclitaxel/carboplatin salvage chemotherapy in noncutaneous versus cutaneous metastatic melanoma. Chang W; Lee SJ; Park S; Choi MK; Hong JY; Kim YS; Maeng CH; Jung HA; Kim S; Lee J Melanoma Res; 2013 Apr; 23(2):147-51. PubMed ID: 23411477 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer. Huang L; Chen S; Yao L; Liu G; Wu J; Shao Z Int J Nanomedicine; 2015; 10():1969-75. PubMed ID: 25792830 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of the combination paclitaxel/carboplatin in patients with previously treated advanced ovarian carcinoma: a multicenter French Groupe des Investigateurs Nationaux pour l'Etude des Cancers Ovariens phase II study. Pujade-Lauraine E; Guastalla JP; Weber B; Curé H; Orfeuvre H; Mousseau M; Vincent P; Diéras V; Tubiana-Mathieu N; Jacquin JP; Mignot L; Leduc B; Paraïso D; Viens P Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-30-S15-35. PubMed ID: 9346219 [TBL] [Abstract][Full Text] [Related]
9. Weekly nab-paclitaxel in combination with carboplatin versus solvent-based paclitaxel plus carboplatin as first-line therapy in patients with advanced non-small-cell lung cancer: final results of a phase III trial. Socinski MA; Bondarenko I; Karaseva NA; Makhson AM; Vynnychenko I; Okamoto I; Hon JK; Hirsh V; Bhar P; Zhang H; Iglesias JL; Renschler MF J Clin Oncol; 2012 Jun; 30(17):2055-62. PubMed ID: 22547591 [TBL] [Abstract][Full Text] [Related]
10. Results of a Phase II Study to Evaluate the Efficacy of Docetaxel and Carboplatin in Metastatic Malignant Melanoma Patients Who Failed First-Line Therapy Containing Dacarbazine. Lee CK; Jung M; Choi HJ; Kim HR; Kim HS; Roh MR; Ahn JB; Chung HC; Heo SJ; Rha SY; Shin SJ Cancer Res Treat; 2015 Oct; 47(4):781-9. PubMed ID: 25687848 [TBL] [Abstract][Full Text] [Related]
11. Atezolizumab plus carboplatin and nab-paclitaxel versus carboplatin and nab-paclitaxel as treatments for Chinese, treatment-naïve, stage IV, non-squamous, non-small-cell lung cancer patients: A retrospective analysis. Chen Y; Kang S; Yan M Pharmacol Res Perspect; 2022 Jun; 10(3):e00941. PubMed ID: 35568997 [TBL] [Abstract][Full Text] [Related]
12. The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. Fujita T; Hiroishi T; Shikano K; Yanagisawa A; Hayama N; Amano H; Nakamura M; Hirano S; Tabeta H; Nakamura S Intern Med; 2018 Jul; 57(13):1827-1832. PubMed ID: 29434143 [TBL] [Abstract][Full Text] [Related]
13. Nab-paclitaxel/bevacizumab/carboplatin chemotherapy in first-line triple negative metastatic breast cancer. Hamilton E; Kimmick G; Hopkins J; Marcom PK; Rocha G; Welch R; Broadwater G; Blackwell K Clin Breast Cancer; 2013 Dec; 13(6):416-20. PubMed ID: 24099649 [TBL] [Abstract][Full Text] [Related]
14. A randomized, controlled phase III trial of nab-Paclitaxel versus dacarbazine in chemotherapy-naïve patients with metastatic melanoma. Hersh EM; Del Vecchio M; Brown MP; Kefford R; Loquai C; Testori A; Bhatia S; Gutzmer R; Conry R; Haydon A; Robert C; Ernst S; Homsi J; Grob JJ; Kendra K; Agarwala SS; Li M; Clawson A; Brachmann C; Karnoub M; Elias I; Renschler MF; Hauschild A Ann Oncol; 2015 Nov; 26(11):2267-74. PubMed ID: 26410620 [TBL] [Abstract][Full Text] [Related]
15. nab-paclitaxel for the management of patients with advanced non-small-cell lung cancer. Hirsh V Expert Rev Anticancer Ther; 2014 Feb; 14(2):129-41. PubMed ID: 24467217 [TBL] [Abstract][Full Text] [Related]
16. Phase II study of nab-paclitaxel and bevacizumab as first-line therapy for patients with unresectable stage III and IV melanoma. Spitler LE; Boasberg P; O'Day S; Hamid O; Cruickshank S; Mesko S; Weber RW Am J Clin Oncol; 2015 Feb; 38(1):61-7. PubMed ID: 25616203 [TBL] [Abstract][Full Text] [Related]
17. Induction chemotherapy with paclitaxel plus carboplatin followed by paclitaxel with concurrent radiotherapy in stage IIIB non-small-cell lung cancer (NSCLC) patients: a phase II trial. Pallarés C; Capdevila J; Paredes A; Farré N; Ciria JP; Membrive I; Basterrechea L; Gomez-Segura G; Barnadas A Lung Cancer; 2007 Nov; 58(2):238-45. PubMed ID: 17658655 [TBL] [Abstract][Full Text] [Related]
18. Sequential versus concurrent paclitaxel and carboplatin for the treatment of advanced non-small cell lung cancer in elderly patients and patients with poor performance status: results of two Phase II, multicenter trials. Marsland TA; Garfield DH; Khan MM; Look RM; Boehm KA; Asmar L Lung Cancer; 2005 Jan; 47(1):111-20. PubMed ID: 15603861 [TBL] [Abstract][Full Text] [Related]
19. Patient-reported neuropathy and taxane-associated symptoms in a phase 3 trial of nab-paclitaxel plus carboplatin versus solvent-based paclitaxel plus carboplatin for advanced non-small-cell lung cancer. Hirsh V; Okamoto I; Hon JK; Page RD; Orsini J; Sakai H; Zhang H; Renschler MF; Socinski MA J Thorac Oncol; 2014 Jan; 9(1):83-90. PubMed ID: 24346096 [TBL] [Abstract][Full Text] [Related]
20. nab-Paclitaxel in Combination With Weekly Carboplatin With Concurrent Radiotherapy in Stage III Non-Small Cell Lung Cancer. Lammers PE; Lu B; Horn L; Shyr Y; Keedy V Oncologist; 2015 May; 20(5):491-2. PubMed ID: 25845992 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]